Human Ebola Virus Species and Compositions and Methods Thereof

Abstract

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

1 . An isolated hEbola virus comprising a nucleic acid molecule comprising a nucleotide sequence of:
 a) a nucleotide sequence set forth in SEQ ID NOS: 1 or 10;   b) a nucleotide sequence hybridizing under stringent conditions to SEQ ID NOS: 1 or 10; or   c) a nucleotide sequence of at least 70%-99% identity to the SEQ ID NOS: 1 or 10, with the proviso that said nucleotide sequence is not SEQ ID NO: 20.   
     
     
         2 . An isolated hEbola virus having Centers for Disease Control Deposit Accession No. 200706291. 
     
     
         3 . The hEbola virus of  claim 1  which is killed. 
     
     
         4 . The hEbola virus of  claim 1  which is an attenuated hEbola virus. 
     
     
         5 . The virus of  claim 4  wherein at least one property of the attenuated hEbola virus is reduced from among infectivity, replication ability, protein synthesis ability, assembling ability or cytopathic effect. 
     
     
         6 . An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS: 1 or 10 or a complement thereof, or a fragment thereof wherein said fragment comprises a nucleotide sequence of between 4 and 4900 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof; with the proviso that said nucleotide sequence is not comprised by the nucleotide sequence set forth in SEQ ID NO: 20; or between 5500 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof. 
     
     
         7 . The isolated nucleic acid molecule of  claim 6  comprising a nucleotide sequence of between 4 and 4900 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof; with the proviso that said nucleotide sequence is not comprised by the nucleotide sequence set forth in SEQ ID NO: 20; or between 5500 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof. 
     
     
         8 . The isolated nucleic acid molecule of  claim 7  comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2-9, 59, or SEQ ID NO: 11-19 or a complement thereof. 
     
     
         9 . An isolated RNA or DNA nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS: 1 or 10 or a complement thereof. 
     
     
         10 . An isolated polypeptide encoded by the nucleic acid molecule of  claim 7 . 
     
     
         11 . The polypeptide of  claim 10  comprising the amino acid of:
 a) an amino acid sequence set forth in any of SEQ ID NOS: 2-19, or 59; or 
 b) an amino acid sequence that has 70%-99% homology to the amino acid sequence of (a). 
 
     
     
         12 . The polypeptide of  claim 10  wherein the amino acid sequence has
 5 to 250 contiguous amino acid residues of the amino acid sequence of SEQ ID NOS: 5 or 18 (VP24); 
 5 to 280 contiguous residues of the amino acid sequence of SEQ ID NOS: 6 or 17 (VP30); 
 5 to 320 contiguous residues of the amino acid sequence of SEQ ID NOS: 8 or 13 (VP40); 
 5 to 340 contiguous residues of the amino acid sequence of SEQ ID NOS: 7 or 12 (VP35); 
 5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS: 4 or 15 (SGP); 
 5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS: 59 or 16 (SSGP); 
 5 to 670 contiguous residues of the amino acid sequence of SEQ ID NOS: 9 or 14 (GP); 
 5 to 730 contiguous residues of the amino acid sequence of SEQ ID NOS: 3 or 11 (NP); or 
 5 to 2200 contiguous residues of the amino acid sequence of SEQ ID NOS: 2 or 19 (L). 
 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . The hEbola virus of  claims 3  or  4 , or a protein extract therefrom, and a pharmaceutically acceptable carrier. 
     
     
         21 . (canceled) 
     
     
         22 . The nucleic acid molecule of  claims 6  or  9 , and a pharmaceutically acceptable carrier. 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled)